NCEL
NewcelX Ltd.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Last price
3.36
▼ 0.01 (0.30%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
3.37
Prev close
3.37
Day high
3.31
Day low
3.22
Volume
1.39K
Market cap
$18.70M
P/E (TTM)
—
52W range
1.83 – 26.90
Day trading desk
Gap from prior close
+0.00%
Prior close 3.37
VWAP
3.25
+3.32% from price
Relative volume
0.04×
Quiet session
Session range
4.81%
3.22 – 3.37
Position in range
94%
Near session high
ATR (14D)
0.26
7.63% of price
Prior day high
3.40
PDH
Prior day low
3.17
PDL
Bid / ask spread
—
Quote not published
Session volume
1.39K
Avg 36.70K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-2.45%
-1.1%
1M
-14.13%
-17.9%
3M
+2.61%
-0.5%
6M
+20.85%
+9.8%
YTD
+71.74%
+59.4%
1Y
-87.82%
-107.8%
3Y
-99.04%
-173.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on NCEL open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
3.64M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Apr 27, 26 | SAMUEL OLIVIER Director |
BUY | 81.82K | $316.64K | Direct |
| Apr 27, 26 | REVEL MICHEL Officer, Director and Beneficial Owner |
BUY | 54.55K | $211.09K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
REVEL MICHEL |
Officer, Director and Beneficial Owner | 957.53K | Purchase |
SAMUEL OLIVIER |
Director | 81.82K | Purchase |
Fundamentals
Market cap$18.70M
Enterprise value$15.60M
Revenue (TTM)—
Gross profit—
EBITDA$-2.51M
Net income$-8.30M
EPS (TTM)$-2.16
Free cash flow$-2.73M
Total cash$2.20M
Total debt$355.00K
Book value / share$1.51
Shares outstanding5.73M
Float2.61M
Short % of float1.33%
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E-5.44
PEG ratio—
Price / sales—
Price / book2.16
EV / revenue—
EV / EBITDA-6.22
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity—
Return on assets-25.94%
Debt / equity4.90
Current ratio0.76
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | — | — |
| Gross profit | — | $0 | $0 | $0 | $0 | — |
| Research & development | $1.13M | $992.00K | $1.61M | $4.28M | — | +13.5% |
| Selling, general & admin | $1.35M | $805.00K | $1.41M | $1.88M | — | +67.5% |
| Total operating expense | $2.47M | $1.80M | $3.02M | $6.25M | — | +37.7% |
| Operating income | -$2.47M | -$1.80M | -$3.02M | -$6.25M | — | -37.7% |
| Net interest income | -$5.74M | -$5.13M | -$317.00K | -$255.68K | — | -11.8% |
| Pre-tax income | -$8.30M | -$7.20M | -$3.33M | -$6.49M | — | -15.3% |
| Tax provision | — | -$8.21K | -$52.68K | -$47.39K | -$142.57K | — |
| Net income | -$8.30M | -$7.20M | -$3.33M | -$6.45M | — | -15.3% |
| Net income to common | -$8.30M | -$7.20M | -$3.33M | -$6.45M | — | -15.3% |
| Basic EPS | -2.16 | -2.43 | -1.13 | -2.59 | — | +11.1% |
| Diluted EPS | -2.16 | -2.43 | -1.13 | -2.59 | — | +11.1% |
| EBIT | -$2.29M | -$2.15M | -$3.09M | -$6.42M | — | -6.5% |
| EBITDA | -$2.24M | -$1.74M | -$2.47M | -$5.87M | — | -28.6% |
| Basic shares | 3.84M | 2.96M | 2.96M | 2.49M | — | +29.9% |
| Diluted shares | 3.84M | 2.96M | 2.96M | 2.49M | — | +29.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $2.20M | $650.00K | $1.09M | $1.81M | — | +238.6% |
| Cash & short-term investments | $2.20M | $650.00K | $1.09M | $1.81M | — | +238.6% |
| Accounts receivable | — | — | — | — | $219.48K | — |
| Total current assets | $3.18M | $780.00K | $1.53M | $2.10M | — | +307.9% |
| Property, plant & equipment | $95.00K | $123.00K | $515.77K | $1.28M | — | -22.8% |
| Goodwill & intangibles | $8.17M | $0 | — | — | — | — |
| Total assets | $11.45M | $903.00K | $2.20M | $3.54M | — | +1,167.4% |
| Total current liabilities | $4.20M | $8.90M | $3.35M | $2.99M | — | -52.9% |
| Current debt | $355.00K | $2.67M | $2.28M | $1.18M | — | -86.7% |
| Long-term debt | — | — | $834.00K | $0 | — | — |
| Total debt | $355.00K | $2.67M | $2.62M | $2.02M | — | -86.7% |
| Total liabilities | $4.20M | $8.90M | $3.35M | $3.45M | — | -52.9% |
| Retained earnings | -$84.89M | -$76.59M | -$65.23M | -$66.86M | — | -10.8% |
| Shareholder equity | $7.25M | -$8.00M | -$1.15M | $92.51K | — | +190.7% |
| Working capital | -$1.01M | -$8.12M | -$1.82M | -$884.51K | — | +87.5% |
| Net tangible assets | -$918.00K | -$8.00M | -$1.15M | $92.51K | — | +88.5% |
| Shares issued | 4.80M | 2.96M | 2.96M | 2.57M | — | +62.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$8.30M | -$7.20M | -$3.33M | -$6.45M | -15.3% |
| Depreciation & amortisation | $55.00K | $413.00K | $620.00K | $550.51K | -86.7% |
| Stock-based compensation | $765.00K | $208.00K | $149.00K | $230.42K | +267.8% |
| Change in working capital | -$1.07M | $736.00K | -$766.00K | -$280.93K | -245.4% |
| Operating cash flow | -$2.77M | -$1.07M | -$3.44M | -$5.67M | -159.5% |
| Capital expenditure | -$8.00K | -$6.00K | -$6.00K | -$181.61K | -33.3% |
| Investing cash flow | $1.70M | -$6.00K | $103.00K | -$186.15K | +28,433.3% |
| Financing cash flow | $2.63M | $450.00K | $2.85M | $1.06M | +484.2% |
| Free cash flow | -$2.77M | -$1.07M | -$3.45M | -$5.86M | -158.8% |
| End cash position | $2.20M | $650.00K | $1.32M | $1.81M | +238.6% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
| Line item | 2025-12-31 | 2025-06-30 | 2024-12-31 | YoY |
|---|---|---|---|---|
| Cash & equivalents | $2.20M | $297.89K | $650.00K | +638.9% |
| Cash & short-term investments | $2.20M | $297.89K | $650.00K | +638.9% |
| Accounts receivable | — | $55.56K | — | — |
| Total current assets | $3.18M | $353.45K | $780.00K | +800.3% |
| Property, plant & equipment | $95.00K | $105.80K | $123.00K | -10.2% |
| Goodwill & intangibles | $8.17M | — | $0 | — |
| Total assets | $11.45M | $459.25K | $903.00K | +2,392.1% |
| Total current liabilities | $4.20M | $15.49M | $8.90M | -72.9% |
| Current debt | $355.00K | $2.54M | $2.67M | -86.0% |
| Total debt | $355.00K | $2.54M | $2.67M | -86.0% |
| Total liabilities | $4.20M | $15.49M | $8.90M | -72.9% |
| Retained earnings | -$84.89M | -$92.95M | -$76.59M | +8.7% |
| Shareholder equity | $7.25M | -$15.03M | -$8.00M | +148.2% |
| Working capital | -$1.01M | -$15.13M | -$8.12M | +93.3% |
| Net tangible assets | -$918.00K | -$15.03M | -$8.00M | +93.9% |
| Shares issued | 4.80M | — | 2.96M | — |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | -1.18 | 1 | $0 | — |
| Next year | -0.60 | 1 | $0 | 0.0% |
Analyst targets & ownership
Mean target$23.00
High target$23.00
Low target$23.00
Implied upside584.52%
Analyst count1
ConsensusNONE
Strong buy / Buy1 / 0
Hold0
Sell / Strong sell0 / 0
Held by insiders68.06%
Held by institutions1.35%
Institutions holding6
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
3.32
+1.06% from price
SMA 20
3.39
-3.72% from price
SMA 50
3.59
-9.04% from price
SMA 100
3.37
-0.31% from price
SMA 200
3.14
+3.90% from price
EMA 12
3.36
+0.08% from price
EMA 26
3.45
-2.61% from price
EMA 50
3.48
-3.48% from price
RSI (14)
44.0
Neutral
MACD (12,26,9)
-0.09
Hist -0.00
ATR (14)
0.26
7.85% of price
Realised vol 30D
58.7%
Annualised
Bollinger upper
3.63
20, 2σ
Bollinger lower
3.15
20, 2σ
50 / 200 cross
Golden
3.59 vs 3.14
Trend bias
Above 200
+3.90%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.19
More volatile than market
Correlation to SPY
0.13
Largely independent
Realised vol 30D
58.7%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-93.2%
Peak to trough
Max drawdown 5Y
-99.8%
Peak to trough
ATR 14
0.26
7.85% of price
Beta (reported)
—
5Y monthly, from filing
Short interest
Shares short
39.22K
Prior 56.02K
Change vs prior
-30.0%
Shorts covering
% of float
1.33%
Normal
% of shares out
0.73%
Against total outstanding
Days to cover
1.2
Liquid
Float
2.61M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 13, 26 | Laidlaw & Co. | INITIATED | — | Buy |
Dividends & splits
Forward rate—
Forward yield—
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:10
Split dateOct 31, 2025
SEC filings
Offering Registrations
F-3 · 2026-08-20
Corporate Changes & Voting Matters
6-K · 2026-08-03
Corporate Changes & Voting Matters
6-K · 2026-07-31
Corporate Changes & Voting Matters
6-K · 2026-07-15
Corporate Changes & Voting Matters
6-K · 2026-07-08
Corporate Changes & Voting Matters
6-K · 2026-07-01
Corporate Changes & Voting Matters
6-K · 2026-06-30
Corporate Changes & Voting Matters
6-K · 2026-06-15
Headlines
NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing
GlobeNewswire · 23d ago
NewcelX Granted Patent in Brazil for NCEL-101 in Type 1 Diabetes, Expanding Global IP Portfolio
GlobeNewswire · 39d ago
NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board
GlobeNewswire · 46d ago
NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes
GlobeNewswire · 53d ago
NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform
GlobeNewswire · 69d ago
NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes
GlobeNewswire · 88d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.